Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market

News provided by

Research and Markets

28 Jul, 2015, 11:12 GMT

DUBLIN, July 20, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/shbcvq/global) has announced the addition of the "Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019" report to their offering.

Continue Reading
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

The global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.

This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography.

Strategic alliances formed, in terms of licensing and collaboration, to help in the co-development and commercialization of drugs in different regions is one of the key trends in the market. Co-development agreements between different companies enable the use of technical expertise from both companies. These agreements also allow the use of regulatory and development experience gained by one company for the support of the pipeline candidates of another company.

According to the report, increased cases of accidents and violence boost market growth. The rise in conflicts between different countries has increased stress levels in individuals worldwide, particularly those in the military. Domestic and social violence also trigger the development of PTSD in people.

Further, the report states that the unavailability of standard diagnostic methods to identify PTSD in people hinders market growth. Currently, the diagnosis is based on criteria set by the American Psychiatric Association; determining patient conformance to the criteria is time-consuming and can lead to misdiagnosis, resulting in inadvertent noncompliance among the population.

Key Vendors

  • GlaxoSmithKline
  • Pfizer
  • Otsuka Pharmaceutical

Other Prominent Vendors

  • Azevan Pharmaceuticals
  • Baylor Research Institute
  • Eli Lilly
  • Forest Laboratories
  • H. Lundbeck
  • Humanetics Pharmaceuticals
  • Marinus Pharmaceuticals
  • Nanotherapeutics
  • Neurocrine Biosciences
  • Novartis Pharmaceuticals
  • Synchroneuron
  • Tonix Pharmaceuticals

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Product Profiles
  6. Introduction
  7. PTSD Overview
  8. Pipeline Analysis
  9. Market Landscape
  10. Market Segmentation by Class of Drug
  11. Geographical Segmentation
  12. Buying Criteria
  13. Market Growth Drivers
  14. Drivers and Their Impact
  15. Market Challenges
  16. Impact of Drivers and Challenges
  17. Market Trends
  18. Trends and Their Impact
  19. Vendor Landscape
  20. Global PTSD Therapeutics Market: Key Takeaways
  21. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/shbcvq/global

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com